Johnson & Johnson Navigates Patent Cliff with Mixed 2Q26 Results

Johnson & Johnson (JNJ) reported a 6.6% increase in sales for the second quarter of 2026, reaching approximately $25.3 billion. Despite this growth, the company faced a significant drag from its drug STELARA, which contributed to a roughly 760 basis points slowdown in the growth of its Innovative Medicine segment.

The company’s newer drug, IMAAVY, is still too small to impact JNJ’s financial profile significantly. However, its broad development program makes it a key focus for the future. JNJ has the financial strength to continue funding this replacement cycle, raising questions about whether this durability is already priced into its valuation.

The investment thesis remains a HOLD with a positive outlook. The company’s ability to sustain earnings and cash flow suggests it can navigate the upcoming patent cliff, but investors should monitor how much of this resilience is reflected in current stock prices.